IHC - CA19.9

IHC – CA19.9 Test

The IHC CA19.9 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CA19.9 (Carbohydrate Antigen 19.9) protein expression in tissue samples. CA19.9 is an important tumor-associated marker commonly expressed in pancreatic, gastrointestinal, hepatobiliary, and certain adenocarcinomas, making it highly valuable for tumor diagnosis and classification.

This test plays an important role in identifying tumor origin, supporting differential diagnosis, and confirming epithelial malignancies involving the digestive system.

The IHC CA19.9 test is commonly used in evaluating:

• Pancreatic adenocarcinoma
• Gastrointestinal tract cancers
• Cholangiocarcinoma (bile duct cancer)
• Gallbladder carcinoma
• Metastatic adenocarcinoma differentiation

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy or surgical specimens using advanced antibody staining methods. Expert pathologists examine stained tissue microscopically to identify CA19.9 protein expression and assess tumor characteristics.

This test is especially helpful when routine histopathology findings are inconclusive or when determining whether a tumor originated from the pancreas, biliary tract, or gastrointestinal system.

Accurate CA19.9 tissue marker analysis supports oncologists in tumor classification, prognosis assessment, and personalized treatment planning.

Benefits of the Test

• Detects CA19.9 protein expression accurately
• Supports pancreatic and GI tumor diagnosis
• Helps identify tumor origin
• Assists cancer subtype classification
• Improves pathology diagnosis accuracy
• Supports personalized oncology treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CA19.9 IHC Test when:

• Pancreatic cancer is suspected
• Gastrointestinal tumor origin requires clarification
• Histopathology findings are inconclusive
• Differential diagnosis is needed
• Metastatic adenocarcinoma evaluation is required
• Biliary tract cancer confirmation is necessary
• Personalized treatment planning depends on exact diagnosis
• Advanced oncopathology classification is needed

This test improves diagnostic confidence for accurate cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CA19.9 IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected pancreatic tumors
• Individuals requiring GI tumor classification
• Patients undergoing hepatobiliary cancer evaluation
• Individuals with unclear tissue diagnosis
• Oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate CA19.9 IHC reports for reliable diagnosis and personalized cancer treatment planning.